About us

LaFleur, the French laboratory for plant innovation

About us

LaFleur, the French laboratory for plant innovation

About us

LaFleur, the French laboratory for plant innovation

Who is LaFleur ?

Since 2014, thanks to his participation in numerous international conferences, Franck Milone, in his capacity as CEO, has developed his expertise in the field of research and innovation of products derived from cannabis.

LaFleur helps to advance cannabis research. Many of the studies are conducted in partnership with university research institutions and major private and public laboratories. LaFleur is also involved in several research projects on varietal selection and standardization of cannabis flower production.

LaFleur is a French laboratory and develops drugs to pharmaceutical standards to ensure compliance with quality standards at every stage of the production process.

LaFleur’s commitment to the excellence of its cannabis-based medicines is evident in the security of the systems it has put in place.

  • 2014 - 2018

    International symposiums, elaboration of research and development projects, creation of partnerships and finalization of the production project.

  • 2018 - 2020

    Implementation of research projects, pre-clinical studies, importation of cannabis for pharmaceutical development and fundraising.

  • 2021

    Production of drugs based on foreign cannabis and launch of the agronomic research phase to control the entire value chain (from plant to drug).

  • 2022

    Setting up an early clinical trial.

  • 2023

    Commercialization of the first cannabis-based health products with a therapeutic purpose 100% made in France.

A revolution is underway

Health systems around the world are finding themselves resilient after covid-19. Old paradigms are falling. A society where health is essential is being built.

 In the maelstrom of these transformations, medical innovations emerge: new pharmaceutical specialties created from molecules that no one imagined could be used anymore, original therapeutics that challenge the relationship between patient and doctor.

 Cannabinoids (cannabis molecules) are a formidable example.

 At DelleD, we very quickly understood that this revolution in health needed positive conspirators, pharmacists who translate new patterns and ingenious people who think differently.

There is nothing to prevent them from being both the producers of the new vehicles of this health care and its main beneficiaries. 

This is what has poussé́ Franck Milone, who is also a patient suffering from multiple sclerosis, to take the plunge and to commit himself, as of 2015, to the search for new methods of production and development of these drugs.

 Aware of the increasing expectations of patients regarding their well-being, we are dedicating our efforts to building new ways of producing drugs, starting with cannabis-derived health products, which are now a decisive horizon for research and health. This is why we have created LaFleur, which is completing this large-scale project to meet the needs of our patients.

  • 2014 - 2018

    International symposiums, elaboration of research and development projects, creation of partnerships and finalization of the production project.

  • 2018 - 2020

    Implementation of research projects, pre-clinical studies, importation of cannabis for pharmaceutical development and fundraising.

  • 2021

    Production of drugs based on foreign cannabis and launch of the agronomic research phase to control the entire value chain (from plant to drug).

  • 2022

    Setting up an early clinical trial.

  • 2023

    Commercialization of the first cannabis-based health products with a therapeutic purpose 100% made in France.

A revolution is underway

Health systems around the world are finding themselves resilient after covid-19. Old paradigms are falling. A society where health is essential is being built.

 

In the maelstrom of these transformations, medical innovations emerge: new pharmaceutical specialties created from molecules that no one imagined could be used anymore, original therapeutics that challenge the relationship between patient and doctor.

 

Cannabinoids (cannabis molecules) are a formidable example.

 

At DelleD, we very quickly understood that this revolution in health needed positive conspirators, pharmacists who translate new patterns and ingenious people who think differently.

There is nothing to prevent them from being both the producers of the new vehicles of this health care and its main beneficiaries. This is what has poussé́ Franck Milone, who is also a patient suffering from multiple sclerosis, to take the plunge and to commit himself, as of 2015, to the search for new methods of production and development of these drugs.

 

Aware of the increasing expectations of patients regarding their well-being, we are dedicating our efforts to building new ways of producing drugs, starting with cannabis-derived health products, which are now a decisive horizon for research and health. This is why we have created LaFleur, which is completing this large-scale project to meet the needs of our patients.

 

 

Who is LaFleur ?

Since 2014, thanks to his participation in numerous international conferences, Franck Milone, in his capacity as CEO, has developed his expertise in the field of research and innovation of products derived from cannabis.

LaFleur helps to advance cannabis research. Many of the studies are conducted in partnership with university research institutions and major private and public laboratories. LaFleur is also involved in several research projects on varietal selection and standardization of cannabis flower production.

LaFleur is a French laboratory and develops drugs to pharmaceutical standards to ensure compliance with quality standards at every stage of the production process.

LaFleur’s commitment to the excellence of its cannabis-based medicines is evident in the security of the systems it has put in place.

Translated with www.DeepL.com/Translator (free version)

1606915535815
  • 2014 - 2018

    International symposiums, elaboration of research and development projects, creation of partnerships and finalization of the production project.

  • 2018 - 2020

    Implementation of research projects, pre-clinical studies, importation of cannabis for pharmaceutical development and fundraising.

  • 2021

    Production of drugs based on foreign cannabis and launch of the agronomic research phase to control the entire value chain (from plant to drug).

  • 2022

    Setting up an early clinical trial.

  • 2023

    Commercialization of the first cannabis-based health products with a therapeutic purpose 100% made in France.

A revolution is underway

Health systems around the world are finding themselves resilient after covid-19. Old paradigms are falling. A society where health is essential is being built.

 

In the maelstrom of these transformations, medical innovations emerge: new pharmaceutical specialties created from molecules that no one imagined could be used anymore, original therapeutics that challenge the relationship between patient and doctor.

 

Cannabinoids (cannabis molecules) are a formidable example.

 

At DelleD, we very quickly understood that this revolution in health needed positive conspirators, pharmacists who translate new patterns and ingenious people who think differently.

There is nothing to prevent them from being both the producers of the new vehicles of this health care and its main beneficiaries. This is what has poussé́ Franck Milone, who is also a patient suffering from multiple sclerosis, to take the plunge and to commit himself, as of 2015, to the search for new methods of production and development of these drugs.

 

Aware of the increasing expectations of patients regarding their well-being, we are dedicating our efforts to building new ways of producing drugs, starting with cannabis-derived health products, which are now a decisive horizon for research and health. This is why we have created LaFleur, which is completing this large-scale project to meet the needs of our patients.

 

 

error: Contenu protégé!